The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of the 92-gene assay on cost of diagnosis of tumor type in metastatic cancer of uncertain origin.
Tanya G. Bentley
Research Funding - bioTheranostics
Brock Schroeder
Employment or Leadership Position - bioTheranostics
Stock Ownership - bioTheranostics
Catherine A. Schnabel
Employment or Leadership Position - bioTheranostics
Stock Ownership - bioTheranostics
Jesse Ortendahl
Research Funding - bioTheranostics
Wendy C. Hsiao
Research Funding - bioTheranostics
Mark G. Erlander
Employment or Leadership Position - bioTheranostics
Stock Ownership - bioTheranostics
Michael S. Broder
Research Funding - bioTheranostics